Bio-Techne Lays Out Equity Award Mechanics for Merck KGaA Buyout
TECH sits 65% above its 52-week low of $43.195.
Summary
Bio-Techne's employee FAQ details how equity awards will be handled in the pending $73 per share acquisition by Merck KGaA, including cash conversion of options, RSUs, and PSUs, and the wind-down of the ESPP after the current cycle.
Key Events · M&A and Partnerships · TECH
-
Equity Award Conversion Details
At closing, vested stock options will be cashed out at the $73.00 per share deal price minus the exercise price. Unvested options, RSUs, and PSUs convert to cash awards that continue to vest on their original time-based schedules, with PSUs deemed achieved at maximum performance.
-
ESPP Wind-Down
The current Employee Stock Purchase Plan cycle ends in August 2026. No new participants can enroll, contribution elections cannot be increased, and no new cycle will begin. Accumulated contributions will purchase shares at the end of the cycle.
-
2026 Equity Grant Proceeds as Planned
The scheduled mid-August 2026 equity grant for eligible employees will occur as usual, with stock vehicles and grant values communicated in coordination with the award.
-
Closing Timeline Reiterated
The transaction is expected to close by late 2026 or early 2027, subject to regulatory approvals and Bio-Techne shareholder approval.
Analysis · TECH · Life Sciences
An employee FAQ from Bio-Techne spells out how outstanding equity awards will be treated in the all-cash acquisition by Merck KGaA at $73 per share. At closing, vested options are cashed out for the spread, while unvested options, RSUs, and PSUs convert to cash awards that keep their original vesting schedules—PSUs vest at maximum performance. The current ESPP cycle wraps up in August 2026 with no new cycle, and the planned 2026 equity grant remains on track for mid-August. These provisions are critical for retention and for shareholders assessing deal mechanics, even though the $73 price and the late 2026 to early 2027 closing timeline are unchanged from the June 25 announcement.
At the time of this filing, TECH was trading at $71.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $43.20 to $72.16. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.